Sobi raises 2025 financial forecast after Q3 revenue jumps 21%

[Preliminary]
moxiecreative

Swedish Orphan Biovitrum AB (OTCPK:BIOVF [https://seekingalpha.com/symbol/BIOVF]) has announced a significant upgrade to its full-year 2025 financial outlook [https://seekingalpha.com/pr/20271057-sobi-announces-revised-full-year-outlook-and-advances-publication-of-the-q3-2025-financial], driven by exceptional Q3 performance, disciplined cost control, and strategic pipeline advancements.

The company sees Q3 2025 Group revenue of SEK 7,776 million, marking a robust 21% increase at constant exchange rates compared to the same quarter last year. This surge was primarily fueled by strong in-market sales of key products, particularly Altuvoct, Doptelet, and Gamifant.

The adjusted EBITA margin for Q3 2025 was 47%, driven primarily by lower-than-anticipated R&D spend.

Year-to-date, Sobi's revenue stands at SEK 20,417 million, a 15% increase, with a year-to-date adjusted EBITA margin of 40%.

Based on the accelerated momentum, Sobi has RAISED ITS TARGETS FOR THE FULL FISCAL YEAR: Revenue Growth now expected to be a low double-digit percentage at CER (upgraded from a previous 'high single-digit' percentage). Adjusted EBITA Margin now projected to be in the mid-to-high 30% of revenue (upgraded from a previous 'mid-30'%).

In addition to the strong commercial performance, Sobi highlighted two key corporate developments: First, it received European approval for Tryngolza for familial chylomicronaemia syndrome, with potential in a larger market expected to exceed SEK 5 billion by 2026. Second, Sobi recorded a SEK 6,612 million non-cash impairment charge for Vonjo, which will not impact cash flow.

Sobi will now announce its third quarter report on Monday 20 October 2025 at 08:00 am CEST (moved up from Thursday, October 23, 2025).

MORE ON SWEDISH ORPHAN BIOVITRUM AB (PUBL)

* Swedish Orphan Biovitrum AB (Publ) (SWOBY) Discusses On NASP And Uncontrolled Gout Call (Transcript) [https://seekingalpha.com/article/4823360-swedish-orphan-biovitrum-ab-publ-swoby-discusses-on-nasp-and-uncontrolled-gout-call-transcript]
* Swedish Orphan Biovitrum AB (Publ) (SWOBY) Discusses On NASP And Uncontrolled Gout - Slideshow [https://seekingalpha.com/article/4823346-swedish-orphan-biovitrum-ab-publ-swoby-swedish-orphan-biovitrum-ab-publ-special-call]
* Seeking Alpha’s Quant Rating on Swedish Orphan Biovitrum AB (publ) [https://seekingalpha.com/symbol/SWOBY/ratings/quant-ratings]
* Historical earnings data for Swedish Orphan Biovitrum AB (publ) [https://seekingalpha.com/symbol/SWOBY/earnings]
* Financial information for Swedish Orphan Biovitrum AB (publ) [https://seekingalpha.com/symbol/SWOBY/income-statement]